According to pharmaceutical industry journal PharmaLive, the U.S. Food and Drug Administration has rebuked GlaxoSmithKline for false advertising about its chronic lymphocytic leukemia (CLL) drug Arzerra (ofatumumab). In a letter…
Read More
As a dangerous prescription drug attorney, I was interested in this story about a St. Louis drug manufacturer's guilty plea to two felony counts of criminal fraud. Ethex Corp, a…
Read More
According to a new study that was published in the Journal of Advanced Nursing, institutionalized dementia patients that are given individualized good eating instructions experienced fewer depression symptoms within 6…
Read More
About a month ago, I wrote about an important decision by the Alabama Supreme Court. The court ruled in late January that people hurt by generic drugs may sue the…
Read More
p>Bayer, the makers of the controversial birth control pills Yaz, Yasmin and the generic Ocella, has confirmed reports that it will continue to negotiate settlements with the more than 10,000…
Read More
Patients being treated for epilepsy, depression, migraine, chronic pain, bipolar disorder, and other conditions may need to be vigilant about suicide-related side effects of their treatment. A recent report on…
Read More
According to information first published online in TIME, a study may have discovered the developmental roots of childhood depression. In the study, which was published in the journal Clinical Psychological…
Read More
As a dangerous drug attorney, I was interested to see a recent study adding information to the debate about antidepressants and breast cancer. A Feb. 9 article from HealthDay reports…
Read More
According to the popular health information Web site WebMD, the U.S. Food and Drug Administration has ordered a “black box" warning for Plavix (clopidogrel), a blood thinning drug. That is…
Read More
The FDA issued a warning to patients that Zocor (simvastatin) can cause muscle injury, or myopathy, to those who take the drug at its highest approved dose. Zocor, a statin…
Read More